WILLIAM K PLUNKETT JR to Biotransformation
This is a "connection" page, showing publications WILLIAM K PLUNKETT JR has written about Biotransformation.
Connection Strength
0.161
-
Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Blood. 1996 Jan 01; 87(1):256-64.
Score: 0.033
-
Preclinical characteristics of gemcitabine. Anticancer Drugs. 1995 Dec; 6 Suppl 6:7-13.
Score: 0.033
-
Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia. Clin Cancer Res. 1995 Feb; 1(2):169-78.
Score: 0.031
-
Modulation of arabinosylcytosine metabolism during leukemia therapy. Adv Exp Med Biol. 1994; 370:119-24.
Score: 0.029
-
Cellular pharmacology and optimal therapeutic concentrations of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in leukemic blasts during treatment of refractory leukemia with high-dose 1-beta-D-arabinofuranosylcytosine. Scand J Haematol Suppl. 1986; 44:51-9.
Score: 0.017
-
Metabolism of 9-beta-D-xylofuranosyladenine by the Chinese hamster ovary cell. Mol Pharmacol. 1981 Jul; 20(1):200-5.
Score: 0.012
-
Membrane-permeable dideoxyuridine 5'-monophosphate analogue inhibits human immunodeficiency virus infection. Mol Pharmacol. 1992 Mar; 41(3):441-5.
Score: 0.006